(Singapore, 9 May 2023)
BW LPG Limited (“BW LPG”, the “Company”, OSE ticker code: “BWLPG.OL”) will release its First Quarter 2023 Financial Report and Earnings Presentation at approximately 0700hrs CET on 23 May 2023.
In connection with this release, BW LPG will hold a Financial Results Presentation with Anders Onarheim (CEO), Kristian Sørensen (Deputy CEO and Head of Strategy), Elaine Ong (CFO), and Niels Rigault (EVP, Commercial). The details are as follows:
Date: Tuesday, 23 May 2023
Location Local Time Universal Time
Oslo, Norway 13:00 CET UTC + 1 hours
New York, USA 07:00 EST UTC – 5 hours
Singapore 19:00 SGT UTC + 8 hours
The Financial Results Presentation will be held live via Zoom. Please register in advance at the link below:
A confirmation email will be sent, with information on how to join the Zoom meeting. A recording of the presentation will also be available after the event on the Company’s website at: https://www.bwlpg.com/investors.
For further information, please contact:
Elaine Ong, CPA, CA
Chief Financial Officer
Tel: +65 6705 5506
Head of Corporate Development and Investor Relations
Tel: +65 6705 5519
About BW LPG
BW LPG is the world’s leading owner and operator of LPG vessels, owning and operating Very Large Gas Carriers (VLGC) with a total carrying capacity of over 3 million CBM. With five decades of operating experience in LPG shipping, experienced employees and an in-house LPG trading division, BW LPG offers an integrated, flexible, and reliable service to customers. More information about BW LPG can be found at www.bwlpg.com.
BW LPG is associated with BW Group, a leading global maritime company involved in shipping, floating infrastructure, deepwater oil & gas production, and new sustainable technologies. Founded in 1955 by Sir YK Pao, BW controls a fleet of over 490 vessels transporting oil, gas and dry commodities, with its 200 LNG and LPG ships constituting the largest gas fleet in the world. In the renewables space, the group has investments in solar, wind, batteries, biofuels and water treatment.
This information is subject to disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.